GLP-1 Pills vs Injections: What to Know
Learn the differences between GLP-1 pills and injections, how they work, and what to discuss with a licensed healthcare provider.
Learn the differences between GLP-1 pills and injections, how they work, and what to discuss with a licensed healthcare provider.
If you've heard about GLP-1 medications and are exploring your options, one of the first questions you may have is: Are these available as a pill, or do I need to take an injection?
GLP-1 receptor agonists are a class of medications used to support metabolic health. While most GLP-1 medications are administered by injection, a newer oral form is now available, raising important questions for patients and providers.
This blog breaks down the differences between GLP-1 pills and injections, explains how they’re absorbed in the body, and outlines factors to consider when discussing treatment options with a licensed healthcare provider.
GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone that plays a key role in regulating insulin, blood sugar levels, digestion, and appetite signaling.
GLP-1 receptor agonists are medications that mimic the effects of this hormone. They bind to specific receptors in the body, activating pathways related to metabolic regulation.
GLP-1 medications were initially developed to help manage Type 2 diabetes, but some have since been FDA-approved for chronic weight management in adults with obesity or overweight and certain health conditions. A licensed healthcare provider can help determine whether one of these treatments may be appropriate for your needs.
Both oral and injectable GLP-1s work by activating the same receptor pathways in the body. However, there are important differences in how they are absorbed, dosed, and may be tolerated:
Note: Brand names listed above are FDA-approved for specific conditions and referenced here for educational purposes only. Eden does not manufacture or sell these medications.
{{primary-cta}}
Oral semaglutide (brand name Rybelsus®) is the first GLP-1 receptor agonist approved for use in pill form. To overcome challenges with breakdown in the digestive tract, it includes an absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), which may help deliver semaglutide through the stomach lining.
However, absorption can be inconsistent if the pill isn’t taken exactly as prescribed. Patients are generally instructed to:
These instructions may help ensure enough of the medication reaches the bloodstream to be effective.
Injectable GLP-1s are the most commonly prescribed form of the medication and have a longer history of clinical use. These are typically administered once a week and come in prefilled pens designed for self-injection at home.
Potential advantages include:
Some patients are initially hesitant about injections, but many find the devices simple to use after basic training. A licensed healthcare provider can guide you through the process and explain what to expect.
{{primary-cta}}
Clinical trials suggest that both oral and injectable GLP-1 medications may be effective; however, outcomes may vary depending on the individual, dosage, and formulation.
A 2023 study published in JAMA found that high-dose oral semaglutide (50 mg daily) led to significant weight loss in adults with overweight or obesity who did not have diabetes. While the weight loss outcomes were similar to those seen in previous studies of injectable semaglutide (2.4 mg weekly), the oral form was associated with more frequent gastrointestinal side effects and requires strict daily dosing.
Additionally, other studies comparing oral semaglutide to injectable semaglutide 1.0 mg have shown that while both improve glycemic markers, the injectable form tends to deliver more consistent results at comparable doses.** Nevertheless, some patients may prefer the convenience of pills or may respond better to one form over another, depending on how their body absorbs and tolerates the medication.
That’s why a personalized consultation with a licensed healthcare provider is essential to determine the best approach.
*Oral semaglutide is marketed under the brand name Rybelsus®, but the study evaluated a higher, non-commercial dose (50 mg) than what is currently available in that product. No injectable semaglutide (e.g., Ozempic®, Wegovy®) was tested in this study, although prior injectable trials (such as STEP 1) were referenced for context.
**The PIONEER 4 trial evaluated Rybelsus® (oral semaglutide 14 mg daily), Ozempic® (injectable semaglutide 1.0 mg weekly), and Victoza® (liraglutide 1.8 mg daily) in adults with Type 2 diabetes.
When choosing between a GLP-1 pill and injection, a licensed provider will consider multiple factors, including:
At Eden, patients are connected with independent licensed healthcare providers who take a comprehensive approach to determine whether a GLP-1 medication, and which form, may be right for them when appropriate based on an individual health assessment. Eligibility may not be guaranteed. Eden does not make or manufacture any medications.
{{primary-cta}}
Both oral and injectable GLP-1 receptor agonists share similar potential side effects, including:
These effects are often dose-dependent and may lessen over time. A provider may recommend starting at a lower dose and gradually increasing it to improve tolerability. If side effects persist or are severe, your healthcare provider may consider alternative approaches.
As with any medication, it’s essential to have regular follow-ups with your provider to ensure the treatment plan remains safe and effective.
Choosing between a GLP-1 pill and an injectable formulation depends on more than just convenience; it involves your overall health, daily routine, and how your body responds to treatment.
An independent, licensed healthcare provider accessed via the Eden platform can help you weigh the pros and cons of each option and determine a personalized approach that fits your life.
Understanding how these medications differ is the first step in making an informed decision about your care.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Eden is not a medical provider or a pharmacy. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Medications are filled by independent, state-licensed pharmacies. Eden does not manufacture, own, or dispense any medications. Please consult a licensed healthcare provider before making any medical decisions.
Collins, L., & Costello, R. A. (2024, February 29). Glucagon-Like peptide-1 receptor agonists. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK551568/
Harris, E. (2023). Oral semaglutide led to similar weight loss as injection, the company says. JAMA, 329(23), 2011. https://doi.org/10.1001/jama.2023.9601
Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019). Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. The Lancet, 394(10192), 39–50. https://doi.org/10.1016/s0140-6736(19)31271-1